Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

[Analysis and clinical significance of ETV6 rearrangement in myelodysplastic syndromes patients].

Authors: Ding, Bu-tong  Guo, Nong-jian  Sun, Jian-zhi  Gao, Hong-mei  Wang, Yun-shan  Chen, Yun 
Citation: Ding BT, etal., Zhonghua Xue Ye Xue Za Zhi. 2007 Dec;28(12):804-7.
Pubmed: (View Article at PubMed) PMID:18476590

OBJECTIVE: To identify the ETV6 gene rearrangement in patients with myelodysplastic syndromes (MDS) and explore its relationship with prognosis and disease stages.
METHODS: ETV6 rearrangement in 58 MDS cases were detected by conventional cytogenetics and Split-signal FISH. RT-PCR was used to detect 9p24-12p13 balance translocation with special designed primers ETV6F1/F2 and JAK2R1/R2. The relationship between ETV6 rearrangement and prognosis and disease staging in MDS patients was analyzed.
RESULTS: ETV6 rearrangement were found in 4 (6.9%) of 58 cases, among which ETV6/JAK2 fusion was identified by RT-PCR in 1 (1.7%) case. The mean follow-up duration was 12 months. All 4 patients (100%) with rearrangement transformed into acute leukemia, with a median survival time (MS) of 7 months; while 10 patients (17%) in the non-translocation group transformed to acute leukemia, with a MS of 28 months. In addition, all 4 patients (100%) with rearrangement were in advanced stage of MDS( RAEB), while 17 cases (31.5%) in non-rearrangement group were in that stage.
CONCLUSIONS: ETV6 rearrangement has higher expression rate (6.9%), and is closely associated with disease stage and prognosis in MDS.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 10450605
Created: 2016-01-19
Species: All species
Last Modified: 2016-12-30
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.